Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARVN Arvinas Holding Company LLC

Trading 02-13 12:39:39 EST

11.99

+0.16

+1.31%

High12.50	Low11.92	Vol356.95K
Open12.20	D1 Closing11.84	Amplitude4.94%
Mkt Cap770.05M	Tradable Cap770.05M	Total Shares64.22M
T/O4.33M	T/O Rate0.56%	Tradable Shares64.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":11.99,"timestamp":1771004376766,"preClose":11.835,"halted":0,"volume":356947,"delay":0,"changeRate":0.013096746937051065,"floatShares":64224294,"shares":64224294,"eps":-0.80523,"marketStatus":"Trading","change":0.155,"latestTime":"02-13 12:39:39 EST","open":12.2,"high":12.5,"low":11.915,"amount":4333699.595099,"amplitude":0.04943,"askPrice":12,"askSize":1217,"bidPrice":11.97,"bidSize":462,"shortable":0,"etf":0,"ttmEps":-0.80523,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":11.835,"preHourTrading":{"tag":"盘前","latestPrice":12.18,"preClose":11.835,"latestTime":"09:29 EST","volume":5281,"amount":62493.236318999996,"timestamp":1770992999999,"change":0.345,"changeRate":0.029151,"amplitude":0.056612},"postHourTrading":{"tag":"盘后","latestPrice":11.81,"preClose":11.835,"latestTime":"19:57 EST","volume":11283,"amount":133444.9184,"timestamp":1770944238489,"change":-0.025,"changeRate":-0.002112,"amplitude":0.007605},"volumeRatio":1.008568,"impliedVol":0.6777,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"2610236239","title":"Arvinas Sets CEO Base Salary at $680,000 With Equity and Bonus Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2610236239","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610236239?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:07","pubTimestamp":1770898041,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has announced new compensation terms for Dr. Teel, who has been appointed under an amended and restated employment agreement. Dr. Teel will receive an annual base salary of $680,000 and will be eligible for a performance-based annual cash bonus target of 60% of his base salary. Additionally, Dr. Teel will be granted a stock option to purchase 218,691 shares of common stock and a restricted stock unit award for 147,179 shares, both vesting over four years. In the event of termination without cause or resignation for good reason within 12 months following a change in control, Dr. Teel will be entitled to 18 months of continued base salary, continued health coverage premiums for up to 18 months, a lump sum payment equal to 150% of his target bonus, and full acceleration of unvested equity awards.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2x6b9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2610928033","title":"Arvinas Appoints Randy Teel as President and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2610928033","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610928033?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:00","pubTimestamp":1770897616,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has appointed Randy Teel, Ph.D., as its new President, Chief Executive Officer, and Director. Dr. Teel, who previously served as Chief Business Officer, succeeds John Houston, Ph.D., who is retiring as President, CEO, and Chair but will remain on the Board and provide consulting services. Briggs Morrison, M.D., has been elected Chair of the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL3SqpD1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","BK4112","IE00B3QW5Z07.USD","BK4585","ARVN","LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4007","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2610692879","title":"Arvinas Inc - John Houston to Continue as Board Member and Consultant","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692879?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:00","pubTimestamp":1770897603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA7RQF7D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2610392801","title":"Arvinas Inc - Briggs Morrison Elected as Chair of Arvinas Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2610392801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610392801?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:00","pubTimestamp":1770897603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA7RQF7D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2610192820","title":"Arvinas Inc - John Houston Retires as President and CEO of Arvinas","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192820?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:00","pubTimestamp":1770897603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA7RQF7D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2610923304","title":"Press Release: Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2610923304","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610923304?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:00","pubTimestamp":1770897600,"startTime":"0","endTime":"0","summary":"-- Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth --. Dr. Teel joined Arvinas in 2018 and brings 20 years of biopharmaceutical industry experience with a strong track record of impact. Dr. Teel played a critical role in Arvinas' 2018 initial public offering  and the company's transition to a public, clinical-stage biotechnology company. As CBO, Dr. Teel was responsible for corporate strategy, business development, investor relations, and communications, as well as leadership roles driving strategic initiatives and long-range planning. In earlier roles at Arvinas, Dr. Teel led commercial development and served as Arvinas' interim Chief Financial Officer and Treasurer. Dr. Teel formerly served as Vice President and Head of Strategy at Alexion Pharmaceuticals, where he led long-range planning and partnered with R&D and commercial teams to shape inline and lifecycle man","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007","IPO","CEO"],"gpt_icon":0},{"id":"2610614501","title":"U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday","url":"https://stock-news.laohu8.com/highlight/detail?id=2610614501","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610614501?lang=en_us&edition=fundamental","pubTime":"2026-02-10 15:58","pubTimestamp":1770710313,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday Feb 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including KKR, Sirius XM Hold","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z60LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KD","CGEM","BAM","CRCD","GPOR","KKR","CCUP","AFG","DT","CAH","LU0683600562.USD","LPLA","MCK","NUVL","LU2360107671.USD","ARES","RGNX","CRCO","LU0310800965.SGD","ICHR","COR","BX","CRCA","CRCG","PANW","CMS","LU0203345920.USD","EXEL","COGT","SIRI","FANG","GLTO","AMKR","BDX","DVN","ARVN","APO","APA","BBOT","IE00B19Z4B17.USD","RAL","FTAI","LU2360107325.USD","CELC","GPI","CRCL","EXE","MNST","FLNC"],"gpt_icon":0},{"id":"2601089011","title":"Arvinas Raised to Buy From Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601089011?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:38","pubTimestamp":1767706680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 08:38 ET (13:38 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2601892049","title":"Citigroup Upgrades Arvinas to Buy From Neutral, Adjusts Price Target to $15 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892049","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892049?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:55","pubTimestamp":1767704152,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) has an average rating of overweight and mean price target of $12.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2601086401","title":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601086401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601086401?lang=en_us&edition=fundamental","pubTime":"2026-01-06 15:53","pubTimestamp":1767686032,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR InfrastructureJan 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL8N3Y7095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMT","BKD","BC","BKNG","ARCT","BBBY","LU2249611893.SGD","IE00B5TLWC47.USD","BK4178","BAC","ARVN","BK4532","ALGT","LU0757428866.USD","LU2125154935.USD","AIG","BK4135","BBWI","BK","AEO","ALK","BIIB","BLTE","BA","BALL","BOW","APGE","BRLT","ALL","ACAD","SGXZ23171101.USD","AVY","AXSM","AGIO","AJG","AGNC","BMY","BP","ALHC","SG9999014005.SGD","AAL","BBIO","NLY","ALB","ADAM","ALNY","DRUG","LU0971096721.USD","WMS","EAT"],"gpt_icon":1},{"id":"2592127149","title":"Arvinas Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2592127149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592127149?lang=en_us&edition=fundamental","pubTime":"2025-12-18 01:44","pubTimestamp":1765993440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 12:44 ET (17:44 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2592964351","title":"U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2592964351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592964351?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:13","pubTimestamp":1765955630,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range ResourcesDec 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL8N3XN0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","FOLD","ATO","LU1280957306.USD","LU0957791311.USD","BK4076","AWK","CCCC","IE00BN29S564.USD","AEE","IE00BJJMRZ35.SGD","BBY","BETA","BK4581","BK4588","CHRW","LU0106831901.USD","BK4209","BSX","AMAT","ARWR","BAC","LU2106854487.HKD","ALB","AAP","AEP","AGYS","EAT","LU1061106388.HKD","ANAB","BDX","BRZE","AMPL","BALY","AIR","ASAN","LNT","ALLY","ABNB","SAM","ADSK","BLK","WHD","APGE","BK4197","ADC","CCL","AJG","AXP","AVTR"],"gpt_icon":0},{"id":"2589825151","title":"Arvinas Announces Phase 1 Trial of ARV-393 and Glofitamab Combination for Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825151","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825151?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:05","pubTimestamp":1765026310,"startTime":"0","endTime":"0","summary":"Arvinas Inc. announced new preclinical data supporting the combination of ARV-393, a PROTAC BCL6 degrader, with glofitamab, a CD20×CD3 bispecific antibody, as a potential chemotherapy-free treatment strategy for diffuse large B-cell lymphoma . The results were presented at the 2025 American Society of Hematology  Annual Meeting and Exposition. In a humanized high-grade B-cell lymphoma cell line-derived xenograft model, the combination demonstrated significantly enhanced tumor growth inhibition and increased tumor regression compared to either agent alone. Arvinas plans to initiate a Phase 1 clinical trial cohort evaluating the ARV-393 and glofitamab combination in patients with DLBCL in 2026 and expects to share clinical data from the ongoing Phase 1 trial of ARV-393 in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL7425zt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","ARVN","BK4588","BK4112","NDAQ","BK4007","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2585829461","title":"Arvinas Highlights Vepdegestrant Breast Cancer Data at 2025 SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2585829461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585829461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985616,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has announced that multiple abstracts related to vepdegestrant , an investigational PROTAC estrogen receptor degrader, have been accepted for presentation at the upcoming 2025 San Antonio Breast Cancer Symposium , scheduled for December 9-12, 2025. The presentations will include subgroup analyses from the phase 3 VERITAC-2 trial comparing vepdegestrant to fulvestrant in ER-positive/HER2-negative advanced breast cancer, circulating tumor DNA biomarker analyses from a phase 1/2 study, and early clinical data on the combination of vepdegestrant with the KAT6 inhibitor PF-07248144. The results will be presented at the symposium and full abstracts are available via the SABCS online program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8kF9JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","BK4007","LU2210150020.SGD","ARVN","NDAQ","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2584925074","title":"Arvinas Q3 Revenue USD 41.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925074","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925074?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570317,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Arvinas Q3 operating expenses USD 85.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:54.667 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbnGZhG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2584951336","title":"Arvinas Up Over 21%, On Track for Largest Percent Increase Since December 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2584951336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584951336?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:59","pubTimestamp":1763481540,"startTime":"0","endTime":"0","summary":"Arvinas, Inc.  is currently at $13.38, up $2.34 or 21.23%. --Would be highest close since March 10, 2025, when it closed at $17.56. --On pace for largest percent increase since Dec. 6, 2023, when it rose 30.77%. --Currently up three consecutive days; up 32.25% over this period. --Down 87.59% from its all-time closing high of $107.87 on July 29, 2021. --Down 38.15% from 52 weeks ago , when it closed at $21.64. --Down 49.91% from its 52-week closing high of $26.72 on Nov. 29, 2024. --Traded as high as $13.60; highest intraday level since March 10, 2025, when it hit $18.45. --Up 23.19% at today's intraday high; largest intraday percent increase since Dec. 6, 2023, when it rose as much as 33.75%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"1182005516","title":"Stock Track | Arvinas Soars 5.08% as Stephens Raises Price Target and Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1182005516","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182005516?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:05","pubTimestamp":1762787153,"startTime":"0","endTime":"0","summary":"Shares of Arvinas Holding Company LLC (ARVN) are soaring 5.08% in Monday's intraday trading session, following positive analyst actions from Stephens & Co. The biotechnology company's stock is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ARVN"],"gpt_icon":0},{"id":"2582872072","title":"Arvinas Is Maintained at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872072?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:23","pubTimestamp":1762784580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:23 ET (14:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581094600","title":"Arvinas Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094600?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:37","pubTimestamp":1762439820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 09:37 ET (14:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581195721","title":"Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581195721","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581195721?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:06","pubTimestamp":1762344367,"startTime":"0","endTime":"0","summary":"Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40.96 percent. This is a 29.41 percent increase over losses of $(0.68) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649256/arvinas-q3-eps-0-48-beats-0-81-estimate-sales-41-900m-beat-23-600m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":-0.0868},{"period":"1month","weight":-0.037},{"period":"3month","weight":0.1197},{"period":"6month","weight":0.6693},{"period":"1year","weight":-0.3407},{"period":"ytd","weight":-0.0021}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.038223},{"month":2,"riseRate":0.5,"avgChangeRate":-0.004759},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.187738},{"month":4,"riseRate":0.571429,"avgChangeRate":0.096543},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.132272},{"month":6,"riseRate":0.857143,"avgChangeRate":0.012839},{"month":7,"riseRate":0.714286,"avgChangeRate":0.109648},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06004},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.073956},{"month":10,"riseRate":0.5,"avgChangeRate":0.007881},{"month":11,"riseRate":0.75,"avgChangeRate":0.171233},{"month":12,"riseRate":0.5,"avgChangeRate":0.349087}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction